Why Boston Scientific Corporation’s (BSX) Stock Is Up 5.01%
As of Monday, November 02, Boston Scientific Corporation’s BSX share price has surged by 5.01%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Jenna Brashear
| Share Statistics | BSX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $62,370.8 | $372.7 | 95% |
|
| Shares Out (Mil) | 1,452.0 | 41.4 | 96% |
|
| Institutional Ownership | 99.8% | 84.0% | 94% |
|
| Float (Mil) | 1,445.0 | 35.6 | 93% |
|
| Beta | 0.58 | 0.87 | 33% |
|
| Avg Daily Volume (000s) | 16,741 | 323 | 98% |
|
| Price Change (52-week) |
(58.1%) | 57.5% | 17% |
|
| Growth | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 11.8% | 73% |
|
| Net Income (5yr) | 106.3% | (5.7%) | 99% |
|
| EPS (5yr) | 91.8% | 10.6% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 1.2% | (15.8%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 23 | 28 | 28 | |
| Current EPS | $0.776 | $3.172 | $3.131 | |
| Month Ago EPS | $0.833 | $3.245 | $3.377 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.837 | $3.304 | $3.438 | |
| Year/Year Chg | 94.0% | 63.5% | 73.3% | |
| Financials | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $21,070 | $125 | 91% |
|
| Net Income (TTM) (Mil) | $3,502 | ($9) | 95% |
|
| EPS (TTM) | $2.380 | ($0.300) | 73% |
|
| Operating Cash Flow (TTM) (Mil) | $4,234 | ($1) | 94% |
|
| Net Cash Flow (TTM) (Mil) | ($679) | $2 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $10,909 | $21 | 92% |
|
| Enterprise Value (Q1) (Mil) | $75,857 | $381 | 95% |
|
| Valuation | BSX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.43 | 2.58 | 63% |
|
| P/E | 18.2 | 25.8 | 50% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.3 | 9% |
|
| Ratios | BSX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.0% | 59.5% | 80% |
|
| Net Margin | 16.6% | (4.5%) | 74% |
|
| ROA | 7.9% | (10.1%) | 81% |
|
| ROE | 14.3% | (8.3%) | 69% |
|
| Liabilities to Assets | 43.1% | 45.8% | 34% |
|
| F-Score | 6 | 4 | 67% |
|
Boston Scientific Corporation did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors